Is Theriva Biologics Stock a Good Investment?
Theriva Biologics Investment Advice | TOVX |
- Examine Theriva Biologics' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Theriva Biologics' leadership team and their track record. Good management can help Theriva Biologics navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Theriva Biologics' business and its evolving consumer preferences.
- Compare Theriva Biologics' performance and market position to its competitors. Analyze how Theriva Biologics is positioned in terms of product offerings, innovation, and market share.
- Check if Theriva Biologics pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Theriva Biologics' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Theriva Biologics stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Theriva Biologics is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Abnormally volatile | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Very High | Details | |
Economic Sensitivity | Responds to the market | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Poor | Details | |
Financial Leverage | Inapplicable | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Theriva Biologics Stock
Researching Theriva Biologics' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 21.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 0.14. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Theriva Biologics recorded a loss per share of 32.59. The entity last dividend was issued on the 13th of August 2018. The firm had 1:25 split on the 26th of August 2024.
To determine if Theriva Biologics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Theriva Biologics' research are outlined below:
| Theriva Biologics generated a negative expected return over the last 90 days | |
| Theriva Biologics has high historical volatility and very poor performance | |
| Theriva Biologics may become a speculative penny stock | |
| Theriva Biologics has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (18.35 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Theriva Biologics currently holds about 52.27 M in cash with (19 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.3, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Theriva Biologics has a poor financial position based on the latest SEC disclosures | |
| Latest headline from medcitynews.com: MedCity FemFwd How Celmatix is Using ARPA-Hs Sprint for Womens Health Funding |
Theriva Biologics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Theriva Biologics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Theriva Biologics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 4th of April 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View |
Earnings surprises can significantly impact Theriva Biologics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Theriva Biologics' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-05-07 | 2024-03-31 | -0.34 | -0.3 | 0.04 | 11 | ||
2022-08-11 | 2022-06-30 | -0.35 | -0.31 | 0.04 | 11 | ||
2021-11-03 | 2021-09-30 | -0.25 | -0.2 | 0.05 | 20 | ||
2022-11-10 | 2022-09-30 | -0.39 | -0.33 | 0.06 | 15 | ||
2024-03-25 | 2023-12-31 | -0.41 | -0.34 | 0.07 | 17 | ||
2022-03-16 | 2021-12-31 | -0.3 | -0.4 | -0.1 | 33 | ||
2023-11-13 | 2023-09-30 | -0.37 | -0.19 | 0.18 | 48 | ||
2020-11-10 | 2020-09-30 | -1.7 | -1.4 | 0.3 | 17 |
Theriva Biologics' market capitalization trends
The company currently falls under 'Nano-Cap' category with a current market capitalization of 3.56 M.Market Cap |
|
Theriva Biologics' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.62) | (0.65) | |
| Return On Capital Employed | (0.44) | (0.42) | |
| Return On Assets | (0.33) | (0.35) | |
| Return On Equity | (0.46) | (0.49) |
Determining Theriva Biologics' profitability involves analyzing its financial statements and using various financial metrics to determine if Theriva Biologics is a good buy. For example, gross profit margin measures Theriva Biologics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Theriva Biologics' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Theriva Biologics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Theriva Biologics. Check Theriva Biologics' Beneish M Score to see the likelihood of Theriva Biologics' management manipulating its earnings.
Evaluate Theriva Biologics' management efficiency
Theriva Biologics has return on total asset (ROA) of (0.2498) % which means that it has lost $0.2498 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5906) %, meaning that it created substantial loss on money invested by shareholders. Theriva Biologics' management efficiency ratios could be used to measure how well Theriva Biologics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.65 in 2024. Return On Capital Employed is likely to rise to -0.42 in 2024. At this time, Theriva Biologics' Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 29.2 M in 2024, whereas Total Current Assets are likely to drop slightly above 14.4 M in 2024.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 61.64 | 109.45 | |
| Tangible Book Value Per Share | 22.11 | 21.01 | |
| Enterprise Value Over EBITDA | 0.71 | 0.75 | |
| Price Book Value Ratio | 0.17 | 0.17 | |
| Enterprise Value Multiple | 0.71 | 0.75 | |
| Price Fair Value | 0.17 | 0.17 | |
| Enterprise Value | -29.8 M | -28.3 M |
The leadership approach at Theriva Biologics' fosters a culture of excellence and accountability. Our analysis examines how this culture influences financial outcomes and stock valuation.
Beta 1.338 |
Basic technical analysis of Theriva Stock
As of the 27th of November, Theriva Biologics has the Coefficient Of Variation of (2,205), risk adjusted performance of (0.03), and Variance of 175.27. In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Theriva Biologics, as well as the relationship between them.Theriva Biologics' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Theriva Biologics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Theriva Biologics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Theriva Biologics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Kraws Jeffrey J over six months ago Acquisition by Kraws Jeffrey J of 110000 shares of Theriva Biologics subject to Rule 16b-3 |
Understand Theriva Biologics' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Theriva Biologics' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.03) | |||
| Market Risk Adjusted Performance | (0.43) | |||
| Mean Deviation | 8.0 | |||
| Coefficient Of Variation | (2,205) | |||
| Standard Deviation | 13.24 | |||
| Variance | 175.27 | |||
| Information Ratio | (0.06) | |||
| Jensen Alpha | (0.78) | |||
| Total Risk Alpha | (2.70) | |||
| Treynor Ratio | (0.44) | |||
| Maximum Drawdown | 67.47 | |||
| Value At Risk | (24.57) | |||
| Potential Upside | 34.29 | |||
| Skewness | 1.08 | |||
| Kurtosis | 3.5 |
| Risk Adjusted Performance | (0.03) | |||
| Market Risk Adjusted Performance | (0.43) | |||
| Mean Deviation | 8.0 | |||
| Coefficient Of Variation | (2,205) | |||
| Standard Deviation | 13.24 | |||
| Variance | 175.27 | |||
| Information Ratio | (0.06) | |||
| Jensen Alpha | (0.78) | |||
| Total Risk Alpha | (2.70) | |||
| Treynor Ratio | (0.44) | |||
| Maximum Drawdown | 67.47 | |||
| Value At Risk | (24.57) | |||
| Potential Upside | 34.29 | |||
| Skewness | 1.08 | |||
| Kurtosis | 3.5 |
Consider Theriva Biologics' intraday indicators
Theriva Biologics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Theriva Biologics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Theriva Biologics time-series forecasting models is one of many Theriva Biologics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Theriva Biologics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Theriva Stock media impact
Far too much social signal, news, headlines, and media speculation about Theriva Biologics that are available to investors today. That information is available publicly through Theriva media outlets and privately through word of mouth or via Theriva internal channels. However, regardless of the origin, that massive amount of Theriva data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Theriva Biologics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Theriva Biologics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Theriva Biologics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Theriva Biologics alpha.
Theriva Biologics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Theriva Biologics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Theriva Biologics Corporate Management
| Steven CPA | CFO, CEO | Profile | |
| Vincent Perrone | Director Communication | Profile | |
| Frank Tufaro | Chief Officer | Profile | |
| Vince Wacher | Head Development | Profile | |
| Lara Guzman | Director Operations | Profile | |
| Ramon Alemany | Senior Board | Profile | |
| Michael MD | Senior Development | Profile |
Additional Tools for Theriva Stock Analysis
When running Theriva Biologics' price analysis, check to measure Theriva Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Theriva Biologics is operating at the current time. Most of Theriva Biologics' value examination focuses on studying past and present price action to predict the probability of Theriva Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Theriva Biologics' price. Additionally, you may evaluate how the addition of Theriva Biologics to your portfolios can decrease your overall portfolio volatility.